NIH oncology peer reviewers are protesting the outcome of a recent meeting in which their own grant applications fared so poorly that the reviewers said they were penalized for their service.
Also in this 8-page issue: FISH assay predicts survival on Iressa, Univ. of Colorado Cancer Center study finds.
FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits
- What happened at FDA? Replimune approval raises questions
- I grew up unhoused. Now, with support from ACS, I am an MD-PhD student focused on oncology
My mother instilled in me: “Never become a product of your circumstances.” - Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab
- FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial









